

### NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


## **Single Technology Appraisal**

# Palopegteriparatide for treating chronic hypoparathyroidism ID6380

### **Final Stakeholder List**


Provisional Consultees	Provisional Commentators (no right to
	submit or appeal)
Company	<u>General</u>
Ascendis Pharma	All Wales Therapeutics and Toxicology
(palopegteriparatide)	Centre
	Allied Health Professionals Federation
Patient/carer groups	Board of Community Health Councils in
Amend	Wales
Butterfly Thyroid Cancer Trust	British National Formulary
British Thyroid Foundation	Care Quality Commission
Kidney Care UK	Department of Health - Northern Ireland
National Kidney Federation	Healthcare Improvement Scotland
Parathyroid UK	Medicines and Healthcare products
South Asian Health Foundation	Regulatory Agency
Specialised Healthcare Alliance	National Association of Primary Care
Thyroid UK	<ul> <li>National Pharmacy Association</li> </ul>
	NHS Confederation
Healthcare professional groups	Scottish Medicines Consortium
<ul> <li>Association of Anaesthetists</li> </ul>	Welsh Government
<ul> <li>Association of Surgeons of Great</li> </ul>	Welsh Health Specialised Services
Britain and Ireland	Committee
British Association of Endocrine and	
Thyroid Surgeons	Possible comparator companies
British Association of Surgical	AAH Pharmaceuticals (alfacalcidol,
Oncology	calcitriol, calcium carbonate, calcium
British Geriatrics Society	gluconate, teriparatide)
British Society for Haematology	Accord Healthcare UK (calcium
British Thyroid Association	carbonate, calcium gluconate)
Royal College of Anaesthetists	Alliance Healthcare (alfacalcidol,
Royal College of General Practitioners	calcitriol)
Royal College of Nursing	Atnahs Pharma UK (calcitriol,      Atnahs Pharma UK (calcitriol)
Royal College of Pathologists	chlortalidone, hydrochlorothiazide)
Royal College of Physicians	Aurobindo Pharma     (hydraehlarethiazida)
Royal College of Radiologists	(hydrochlorothiazide)
Royal College of Surgeons	B.Braun Medical (calcium gluconate)      Beatringer Ingellering
Royal Pharmaceutical Society	Boehringer Ingelheim     (hydrochlorothiozida)
Royal Society of Medicine	(hydrochlorothiazide)
Society for Endocrinology	Brown & Burk UK (hydrochlorothiazide)     Creacent Pharma (alfacelaide)
UK Clinical Pharmacy Association	Crescent Pharma (alfacalcidol)
UK Kidney Association	

Final stakeholder list for the evaluation of palopegteriparatide for treating chronic hypoparathyroidism ID6380



Provisional Consultees	Provisional Commentators (no right to
	submit or appeal)
Othora	Daiichi Sankyo UK     (hydraehlarathiazida)
Others	(hydrochlorothiazide)
Department of Health and Social Care     NUC Front and	Eli Lilly (teriparatide)
NHS England	Essential Healthcare (alfacalcidol,
	calcium carbonate)
	Forum Health Products (calcium
	carbonate)
	Galderma UK (calcitriol)
	Galen (calcium carbonate)
	Gedeon Richter UK (teriparatide)
	Glenmark Pharmaceuticals
	(hydrochlorothiazide)
	Grunenthal (calcium carbonate)
	Haleon UK (calcium carbonate)
	HealthAid (calcium carbonate)
	Hameln Pharma (calcium gluconate)
	Internis Pharmaceuticals (calcium
	carbonate)
	Mylan (calcium carbonate,
	hydrochlorothiazide)
	Kyowa Kirin (calcium carbonate)
	Medihealth Northern (alfacalcidol,
	calcitriol, chlortalidone)
	Mylan (bendroflumethiazide,
	indapamide)
	Morningside Healthcare (chlortalidone)
	Neon Healthcare (alfacalcidol, calcium)
	carbonate)
	Novartis Pharmaceuticals
	(hydrochlorothiazide)
	Organon Pharma UK
	(hydrochlorothiazide)
	Pfizer (hydrochlorothiazide)
	Phoenix Healthcare Distribution
	(alfacalcidol, calcitriol, calcium
	carbonate)
	Ranbaxy UK (teriparatide)
	Roche Products (calcitriol)
	Sandoz (calcium carbonate)
	<ul><li>Sandoz (calcidif carbonate)</li><li>Sanofi (hydrochlorothiazide)</li></ul>
	<ul> <li>Sigma Pharmaceuticals (alfacalcidol,</li> </ul>
	bendroflumethiazide, calcitriol,
	chlortalidone, hydrochlorothiazide,
	indapamide)
	. ,
	Stirling Anglian Pharmaceuticals     (calcium carbonate)
Linal stakeholder list for the evaluation of palopegtering	(calcium carbonate)

Final stakeholder list for the evaluation of palopegteriparatide for treating chronic hypoparathyroidism ID6380



Provisional Consultees	Provisional Commentators (no right to
	submit or appeal)
	<ul> <li>Strides Pharma (alfacalcidol)</li> <li>Takeda UK (calcium carbonate, recombinant human parathyroid hormone)</li> <li>Teva UK (calcitriol, teriparatide)</li> <li>Theramex (alfacalcidol)</li> <li>Thornton and Ross (teriparatide, hydrochlorothiazide)</li> <li>TriOn Pharma (alfacalcidol, calcium)</li> </ul>
	<ul><li>carbonate)</li><li>Wockhardt UK (chlortalidone, hydrochlorothiazide)</li></ul>
	<ul> <li>Relevant research groups</li> <li>Cochrane Metabolic &amp; Endocrine Disorders Group</li> <li>Cochrane Haematology</li> <li>Genomics England</li> <li>MRC Clinical Trials Unit</li> <li>National Institute for Health Research</li> </ul>
	<ul><li>Associated Public Health groups</li><li>Public Health Wales</li><li>UK Health Security Agency</li></ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.


#### **Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.





The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

#### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.